Development of assay for determination of eletriptan hydrobromide in loaded PLGA nanoparticles

Eletriptan Hydrobromide is a serotonin 5-HT1 receptor agonist and it used for the treatment of migraine headaches with or without aura. Even if the drug is well absorbed after oral administration, it has some drawbacks like first pass metabolism and decrease in bioavailability after migraine attacks. Encapsulation of drug into polymeric nanoparticles is one of the methods for protecting the drug against degradation. The present work described a preparation of Eletriptan Hydrobromide loaded poly (d,l-lactide-co-glycolide) nanoparticles prepared using o/w single emulsion solvent evaporation method. In order to determine the factors affecting the physicochemical properties of the nanoparticles on the particle size of poly (d,l-lactide-co-glycolide) nanoparticles, D-Optimal design is used. Moreover, novel, simple, sensitive, selective, and fully validated chromatographic technique for the quantification of Eletriptan Hydrobromide from Eletriptan Hydrobromide loaded poly(d,l-lactide-co-glycolide) nanoparticles was developed. Poly(d,l-lactide-co-glycolide) concentration, sonication time and sonication energy were found as significant factors (p < 0.05) on particle size of nanoparticles. Limit of detection and limit of quantification values were calculated as 0.28 μg mL−1and 0.86 μg mL−1, respectively.